Featured Image: American Society of Hematology | Annual Meeting. Courtesy: © 2017. American Society of Hematology. Used with permission.
Featured Image: American Society of Hematology | Annual Meeting. Courtesy: © 2017. American Society of Hematology. Used with permission.

With the 61st annual meeting of the American Society of Hematology about to begin, here are some of the presentations to look for.

This year expect 15 oral and poster presentations covering brentuximab vedotin (Adcetris®, Seattle Genetics/Takeda), an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas.

The drug, which is one of five approved and commercially available antibody-drug comjugates, is being evaluated globally as the foundation of care for CD30-expressing lymphomas in more than 70 corporate- and investigator-sponsored clinical trials.

“At this year’s ASH meeting, [brentuximab vedotin] … will be featured in  … updated analyses from ECHELON-1 and ECHELON-2 phase III frontline trials,” noted Roger Dansey, MD, Chief Medical Officer at Seattle Genetics.

Advertisement #2
 

“We are encouraged by the ECHELON-1 update supporting a sustained progression-free survival benefit for brentuximab vedotin in combination with AVD when compared to ABVD in advanced classical Hodgkin lymphoma and additional analyses from trials evaluating ADCETRIS in combination with nivolumab. We continue to invest in our ADCETRIS clinical development program with the goal of improving outcomes for patients,” Dansey concluded

TitlePresented AbstractSessionDate /Time Location
Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085P. Rubinstein, Rush University Medical Center, Chicago, Ill.130Oral presentation Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin LymphomaSaturday, December 7, 10:15 a.m. ET

Tangerine 2 (WF2)

Brentuximab Vedotin in First Refractory/Relapsed Classical Hodgkin Lymphoma Patients Treated By Chemotherapy (ICE) before Autologous Transplantation. Final Analysis of Phase II StudyA. Stamatoullas, Departement d’Hematologie, Centre Henry Becquerel, Rouen, France132Oral presentation Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Combination Chemotherapy and Biomarkers of Response in Hodgkin LymphomaSaturday, December 7, 10:45 a.m. ET

Tangerine (WF2)

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥ 60 YearsC. Yasenchak, Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, Oregon.237Oral presentation Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Immunotherapy Approaches in Hodgkin LymphomaSaturday, December 7, 2:30 p.m. ET

W224

Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma: Long-term Follow-up Results from the Single-arm Phase 1/2 StudyA. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, N.Y.238Oral presentation Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Immunotherapy Approaches in Hodgkin LymphomaSaturday, December 7, 2:45 p.m. ET

W224

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin as Pre-Transplant Salvage for Hodgkin Lymphoma1555Poster PresentationSaturday, December 7, 5:30-7:30 p.m. ET

Hall B

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) as Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ LymphomasW. Pearse, Loyola University Medical Center, Maywood, Ill.351Oral presentation Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Prospective Clinical Trials: Optimizing Frontline ChemotherapySunday, December 8, 8:00 a.m. ET

Hall E2

 

An Exploratory Analysis of Brentuximab Vedotin plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell TransplantK. Savage, British Columbia Cancer Centre for Lymphoid Cancer, University of British Columbia and the Department of Medical Oncology, Vancouver, B.C., Canada464Oral presentation Hodgkin Lymphoma and T/NK Cell Lymphoma – Clinical Studies: Novel Therapies in Peripheral T-cell LymphomasSunday, December 8, 12:15 p.m. ET

Valencia D (W415D)

 

A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma2834Poster PresentationSunday, December 8, 6:00-8:00 p.m. ET

Hall B

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma2836Poster PresentationSunday, December 8, 6:00-8:00 p.m. ET

Hall B

Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above2852Poster PresentationSunday, December 8, 6:00-8:00 p.m. ET
Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom3482Poster Presentation Sunday, December 8, 6:00-8:00 p.m. ET

Hall B

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma (PTCL)3492Poster PresentationSunday, December 8, 6:00-8:00 p.m. ET

Hall B

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Expressing Peripheral T-cell Lymphomas4023Poster PresentationMonday, December 9, 6:00-8:00 p.m. ET

Hall B

Brentuximab Vedotin with Chemotherapy for Stage III/IV Classical Hodgkin Lymphoma (cHL): Four-Year Update of the ECHELON-1 Study4026Poster PresentationMonday, December 9, 6:00-8:00 p.m. ET

Hall B

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with cHL, sALCL or other CD30 Expressing PTCL4054Poster PresentationMonday, December 9, 6:00-8:00 p.m. ET

Hall B